Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Pentagon reportedly locked down, hazmat teams responding
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities
June 13, 2024 5:17 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Avidity Biosciences (NASDAQ: RNA) to $45.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This morning, Avidity reported compelling biomarker (>50% reduction in DUX4 related gene panels) and functional strength improvement data in FSHD (a rare muscle disorder) patients treated with... More
